architect™人类CRISPR优化试剂盒

用于优化人类细胞基因组编辑的完整试剂盒

产品号 #(选择产品)

产品号 #100-0470_C

用于优化人类细胞基因组编辑的完整试剂盒

产品组分包括

  • architect™人类CRISPR优化试剂盒,APC(目录#100-0470)
    • architect™Human B2M sgRNA, 2 nmol 64.75µg
    • architect™Cas9核酸酶,100µg(目录#76002)
    • 抗人β -2微球蛋白抗体,克隆35,APC, 25次测试
  • architect™人类CRISPR优化试剂盒,PE(目录#100-0471)
    • architect™Human B2M sgRNA, 2 nmol 64.75µg
    • architect™Cas9核酸酶,100µg(目录#76002)
    • 抗人β -2微球蛋白抗体,克隆35,PE, 25次测试
  • architect™人类CRISPR优化试剂盒,FITC(目录#100-0472)
    • architect™Human B2M sgRNA, 2 nmol 64.75µg
    • architect™Cas9核酸酶,100µg(目录#76002)
    • 抗人β -2微球蛋白抗体,克隆35,FITC, 25次测试
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.

概述

architect™人类CRISPR优化试剂盒是一种基于流式细胞术的试剂盒,旨在实现人类细胞基因组编辑的快速优化。它还可以作为在人类细胞中使用architect™CRISPR-Cas9基因组编辑系统进行实验的阳性对照。该试剂盒包括architect™人B2M sgRNA、architect™Cas9核酸酶和荧光基团偶联的β -2微球蛋白(B2M)抗体。首先必须将architect™Cas9核酸酶与architect™Human B2M sgRNA配合,然后将其送入人细胞,随后培养48 - 96小时。培养后,可以通过收集和处理流式细胞术快速评估编辑效率,使用荧光团偶联的B2M抗体。

该试剂盒已经过测试和验证,可与architect™系列基因组编辑产品一起使用。通过靶向编码普遍表达的细胞表面蛋白的B2M基因,可以使用流式细胞术方法快速定量地评估编辑效率。该技术还可以对编辑成功进行额外的评估,如活力监测和/或细胞类型特异性标记表达的评估

Cell Type
Hematopoietic Stem and Progenitor Cells, Intestinal Cells, Pluripotent Stem Cells, T Cells
 
Species
Human
 
Application
Genome Editing
 
Area of Interest
Immunology, Organoids, Stem Cell Biology
 

Data Figures

Figure 1. ArciTect™ Human CRISPR Optimization Kit Exhibits High Editing Efficiency in hPSCs, T Cells, and CD34+ Hematopoietic Stem and Progenitor Cells (HSPCs)

Cells were electroporated with RNP complexes containing sgRNA targeting B2M complexed with ArciTect™ Cas9 Nuclease protein. The cells were cultured for 72 hours following electroporation and editing efficiency was monitored by flow cytometry to detect loss of B2M expression; n = 3 biological replicates (WLS-1C iPSCs/hPSCs) or n = 3 donors (T cells and CD34+ HSPCs). No EP: non-electroporated controls.

Figure 2. Anti-Human Beta-2-Microglobulin, Clone #35 Conjugates Exhibit Equivalent Performance Across Samples to Monitor B2M Knockout Efficiency Using the ArciTect™ Human CRISPR Optimization Kit

CD34+ HSPCs isolated from two independent donors were electroporated with RNP complexes containing sgRNA targeting B2M complexed with ArciTect™ Cas9 Nuclease protein. The cells were cultured for 96 hours following electroporation and editing efficiency was monitored by flow cytometry to detect loss of B2M expression using anti-human beta-2-microglobulin, clone #35, (A, B) APC-conjugated, (C, D) FITC-conjugated, and (E, F) PE-conjugated. The histograms were derived from gated events of viable (7-AAD-negative) cells. Orange histograms: RNP-electroporated samples; grey histograms: non-electroporated control samples.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
100-0470, 100-0472, 100-0471
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0470
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0470, 100-0472, 100-0471
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0470, 100-0472, 100-0471
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0472
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0471
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

更多信息

更多信息
Species Human
Legal Statement: The purchase of the ArciTect™ products conveys to the purchaser the limited, non-transferable right to use, in accordance with all applicable laws and regulations, the ArciTect™ products and any related material solely for research purposes only, not for any clinical, human, agricultural, veterinary, livestock, or commercial purpose, with no warranty (express or implied) from the owners or assignees of the Patents or STEMCELL Technologies each of whom expressly disclaim any warranty regarding results obtained through the use of the ArciTect™ products, and without any exception the owners or assignees of the Patents or STEMCELL Technologies, or as applicable a director, trustee, officer, employee, agent, faculty, official investigator or student thereof, will not suffer or be exposed to any liability, damages, loss, or expense of any kind whatsoever arising from or related to the use of the ArciTect™ products by a purchaser of same. Distribution of ArciTect™ products by STEMCELL Technologies is covered under at least US 8,697,359, US 8,771,945, US 8,795,965, US 8,865,406, US 8,871,445, US 8,889,356, US 8,889,418, US 8,895,308, US 8,906,616 and foreign equivalents (“Patents”). PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。